As of 2026, the entity formerly known as Anthem Inc., now operating as Elevance Health, Inc. (NYSE: ELV), maintains a market capitalization (market net worth) typically ranging between $125 billion and $145 billion, while its total shareholders' equity (book value net worth) sits at approximately $42 billion.
The transition from Anthem Inc. to Elevance Health in 2022 marked more than a name change; it signaled a fundamental shift from a traditional health insurance provider to a comprehensive health benefits organization. For investors and analysts looking at the "net worth" of this healthcare giant in 2026, it is essential to distinguish between the company's market valuation and its balance sheet strength. This financial snapshot explores the core metrics, revenue drivers, and strategic positioning that define the company’s economic footprint in the current fiscal year.
The Evolution from Anthem Inc. to Elevance Health
To understand the financial standing of Anthem Inc. in 2026, one must first recognize its corporate restructuring. In June 2022, shareholders approved the rebranding to Elevance Health. This was designed to unify the company's diverse portfolio, which includes Anthem Blue Cross Blue Shield (the insurance arm), Wellpoint (government business), and Carelon (healthcare services).
This rebranding was a strategic move to capture more value in the "health services" space rather than just the "health insurance" space. Historically, health insurance companies trade at lower price-to-earnings (P/E) multiples compared to technology-enabled health service firms. By expanding the Carelon brand, Elevance Health has sought to improve its margins and, by extension, its total market net worth. In 2026, the company continues to leverage this multi-brand strategy to navigate the complexities of the U.S. healthcare system.
Defining Net Worth: Market Cap vs. Book Value
When discussing the "net worth" of a Fortune 500 company like Elevance Health, clarity regarding the definition is paramount. There are two primary ways to measure this:
Market Capitalization (Market Net Worth)
Market capitalization represents the total dollar market value of a company's outstanding shares of stock. It is calculated by multiplying the current share price by the total number of outstanding shares. As of 2026, Elevance Health’s market cap reflects investor confidence in its long-term growth, the stability of its Medicare Advantage plans, and the profitability of its pharmacy benefit management (PBM) services.
Shareholders' Equity (Book Value)
This is the "net worth" found on the balance sheet, calculated as total assets minus total liabilities. While market cap accounts for future growth potential and intangible assets like brand value, shareholders' equity provides a snapshot of the tangible residual interest of the stockholders in the company's assets. In the capital-intensive healthcare industry, this figure is a critical measure of solvency and the ability to weather regulatory shifts.
2026 Financial Snapshot: Key Performance Indicators (KPIs)
The following table provides a snapshot of the estimated financial performance of Elevance Health (formerly Anthem Inc.) for the 2026 fiscal year based on historical growth trajectories and current market conditions.
| Financial Metric | 2026 Estimated Value | 2025 Reported Value (Est.) | YoY Growth (%) |
|---|---|---|---|
| Total Revenue | $192.5 Billion | $181.2 Billion | 6.2% |
| Net Income | $8.4 Billion | $7.6 Billion | 10.5% |
| Earnings Per Share (EPS) | $36.50 | $32.80 | 11.3% |
| Market Capitalization | $135.0 Billion | $124.5 Billion | 8.4% |
| Medical Loss Ratio (MLR) | 87.2% | 86.8% | +0.4% |
| Total Assets | $118.0 Billion | $112.5 Billion | 4.9% |
| Shareholders' Equity | $44.2 Billion | $41.8 Billion | 5.7% |
Note: The values provided are based on financial projections and current market trends as of 2026. For exact real-time data, refer to the SEC EDGAR database.
Revenue Streams and Business Segments
Elevance Health’s net worth is supported by four primary business pillars. Understanding these segments is crucial for evaluating how the company generates the cash flow required to maintain its high valuation.
1. Commercial & Specialty Business
This remains the legacy core of the old Anthem Inc. It includes employer-sponsored health plans and individual insurance products. In 2026, this segment focuses heavily on "value-based care," where the company is paid based on patient health outcomes rather than the volume of services provided. This transition has helped stabilize margins despite rising medical inflation.
2. Government Business
Comprising Medicare and Medicaid services, this segment is a significant revenue driver. With the aging U.S. population, Medicare Advantage enrollment has been a consistent source of growth. However, this segment also faces the most regulatory scrutiny, as government reimbursement rates are subject to federal and state budget adjustments.
3. Carelon (Health Services)
Carelon is the growth engine that distinguishes Elevance Health from a pure-play insurer. It includes CarelonRx (pharmacy benefits), Carelon Services (behavioral health, complex care), and Carelon Insights (data analytics). By providing services to both its own insurance members and external health plans, Carelon captures a larger share of the healthcare dollar, significantly boosting the company's overall net worth.
4. Wellpoint
The Wellpoint brand focuses primarily on government-sponsored programs in specific regions. It serves as a streamlined vehicle for managing state-level Medicaid contracts, allowing the company to compete effectively in highly regulated local markets.
Balance Sheet Analysis: Assets and Liabilities
To maintain a net worth exceeding $130 billion, Elevance Health manages a complex balance sheet. In 2026, the company’s asset structure is heavily weighted toward cash equivalents, premiums receivable, and long-term investments.
Asset Composition
The company maintains a massive investment portfolio, primarily in high-grade fixed-income securities. These investments serve as a reserve to pay out future medical claims. Additionally, "Goodwill" remains a large line item on the balance sheet, representing the premium paid for historical acquisitions like Amerigroup and various PBM assets.
Liability Management
The largest liabilities for the company are "Medical Claims Payable"—the money owed to doctors and hospitals for services already rendered to members. Elevance Health also carries a significant amount of long-term debt used to fund acquisitions and share buybacks. In 2026, management has prioritized a debt-to-capital ratio of approximately 35-40%, ensuring the company remains investment-grade according to agencies like Moody’s and S&P Global.
The Role of the Medical Loss Ratio (MLR)
One cannot discuss the financial health of an insurance-based entity without examining the Medical Loss Ratio (MLR). The MLR represents the percentage of premium dollars spent on clinical services and quality improvements versus administrative costs and profit.
Under the Affordable Care Act (ACA), large group insurers must maintain an MLR of at least 85%. In 2026, Elevance Health’s MLR is a critical metric for investors. If the MLR rises too high (e.g., above 88%), it indicates that medical costs (utilization) are outstripping premium increases, which could squeeze profit margins and reduce the company's market net worth. Conversely, if the MLR is too low, the company may be required to issue rebates to policyholders.
Comparative Industry Analysis
In the 2026 healthcare landscape, Elevance Health remains a "Big Three" player alongside UnitedHealth Group (UNH) and CVS Health (CVS).
- UnitedHealth Group: Typically commands a higher market cap (often exceeding $450 billion) due to its massive Optum health services division.
- Elevance Health: Offers a more focused play on the Blue Cross Blue Shield network, often viewed as having a "moat" in specific geographic regions where it is the dominant provider.
- CVS Health: Following its acquisition of Aetna and Oak Street Health, CVS competes directly with Elevance but faces higher retail-related headwinds.
Elevance Health often trades at a more modest P/E ratio than UnitedHealth, which some analysts view as an opportunity for "value" investors, while others see it as a reflection of its slightly lower exposure to diversified health services compared to Optum.
Growth Drivers and Risks for 2026
Several factors influence the trajectory of Elevance Health’s net worth as we move through the mid-2020s.
Potential Upsides
- AI Integration: The company has invested billions into artificial intelligence to automate claims processing and predictive diagnostics within Carelon.
- Carelon Expansion: Continued growth in third-party service contracts for Carelon could lead to multiple expansion (a higher stock price relative to earnings).
- Share Buybacks: Elevance Health has historically been aggressive with share repurchases, which reduces the number of shares outstanding and increases the value of each remaining share.
Key Risks
- Regulatory Changes: Changes to the Medicare Advantage "Star Ratings" system or Medicaid redetermination processes can have immediate impacts on revenue.
- Medical Inflation: If the cost of specialty drugs (such as GLP-1 weight-loss medications) increases faster than the company can raise premiums, margins will suffer.
- Cybersecurity: As a holder of vast amounts of Protected Health Information (PHI), the company faces ongoing risks of data breaches, which can result in massive fines and brand damage.
Frequently Asked Questions
What is the difference between Anthem Inc. and Elevance Health?
Anthem Inc. was the corporate name until 2022. The company rebranded to Elevance Health to reflect its broader focus on "elevating" healthcare through both insurance (Anthem) and services (Carelon).
How does Elevance Health make money?
The company earns revenue through insurance premiums paid by employers and individuals, government reimbursements for Medicare and Medicaid, and service fees through its Carelon division for pharmacy and clinical services.
Is Elevance Health a good investment in 2026?
From a financial perspective, Elevance Health is considered a defensive stock. Its massive cash flow and essential role in the U.S. economy often make it a staple for institutional investors, though it is subject to political and regulatory risks.
What is the "net worth" of Elevance Health per share?
This is often referred to as "Book Value Per Share." In 2026, this figure is approximately $185 to $195 per share. However, the market price of the stock is significantly higher because it factors in future earnings and the value of its brand.
Does the company pay dividends?
Yes, Elevance Health has a consistent history of paying and increasing dividends. In 2026, it remains a favorite for dividend-growth investors, typically offering a yield between 1.2% and 1.6% alongside share buybacks.
Practical Recommendation for Analysts
When evaluating the financial snapshot of the former Anthem Inc. in 2026, do not rely solely on the headline net worth or market capitalization. Instead, perform a "sum-of-the-parts" analysis. Evaluate the Carelon segment as a high-growth service provider and the Anthem insurance segment as a stable, cash-generating utility. The true value of the company lies in how effectively these two sides work together to lower the total cost of care while improving patient outcomes.
For those tracking the stock, monitor the Medical Loss Ratio (MLR) quarterly. A rising MLR in an inflationary environment is the primary threat to the company’s valuation, while a growing contribution from Carelon to the total EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is the primary catalyst for a higher net worth.